In June 2003, the Medicine and Healthcare Products Regulatory Agency of the British Department of Health warned physicians to avoid the off-label use of paroxetine, a selective serotonin-reuptake inhibitor (SSRI) antidepressant, for the treatment of depression in children (18 years of age or younger). This action was taken in response to concern about a possible association between SSRIs and suicidal behavior, which includes a broad range of symptoms ranging from fleeting thoughts of self-harm to attempted suicide. Proprietary data examined by the United Kingdom regulatory agency showed a slight increase in suicidal behavior among patients who were randomly assigned to . . .
No takes yet. Share an insight, caveat, or question.
Vitiello et al. (2004) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: